The company's lead clinical-stage product candidates include mecbotamab vedotin (BA3011), a CAB ADC for treating undifferentiated pleomorphic sarcoma and NSCLC, and ozuriftabmab vedotin (BA3021), a CAB ADC to treat melanoma and squamous cell carcinoma of head and neck. BioAtla achieved FDA alignment on a planned randomized Phase 3 Oz-V trial in 2L+ OPSCC with dual primary endpoints and potential accelerated approval.
Cyborg Score Rationale
BioAtla shows promising clinical data with Phase 3 trial FDA alignment and meaningful preliminary efficacy signals, but faces significant headwinds including a severely depleted market cap ($12.65M), near all-time low stock price, high cash burn, and need for financing. The company is pre-revenue and dependent on clinical trial outcomes.
FDA alignment achieved for Phase 3 ozuriftamab vedotin trial with dual endpoints provides regulatory clarity and accelerated approval pathway potential
Company secured $22.5M in flexible financing including Yorkville SEPA despite severe stock price deterioration, indicating some investor conviction
Current market cap of ~$12.65M severely disconnected from development stage and pipeline value, creating extreme distress valuation risk
Named Competitors
Antibody-Drug Conjugates (ADCs) — Market leader in ADC development with approved solid tumor oncology products
Bispecific T-cell Engagers — Competing in bispecific/CAR-T derived therapeutic approaches
CAB-focused immunotherapy — Various companies developing conditionally-active biologic approaches
Recent Developments
(November 2025) FDA alignment achieved on Phase 3 Oz-V trial for 2L+ OPSCC with dual primary endpoints; Phase 1 BA3182 bispecific data presented at ESMO showing responses
(October 2025) Mecbotamab vedotin (BA3011) demonstrated 21.5 months median OS in heavily pretreated sarcoma patients at SITC conference
(February 2026) Stock reached all-time low of $0.13; company secured $22.5M flexible financing agreement to support operations
Open the full interactive BioAtla, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.